Rheumatoid Arthritis | TreatmentTrends | US | 2015

launch Related Market Assessment Reports

• Vitiligo – Executive Insights – Executive Insights (US)

  May 2023

  Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…

• Dry Eye – Access & Reimbursement – Detailed, Expanded Analysis (US)

  For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…

• Rheumatoid Arthritis – Landscape & Forecast – Disease Landscape & Forecast

  Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…

• Obesity/Overweight – Unmet Need – Detailed, Expanded Analysis (US/EU)

  May 2023

  Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Since 2012,…

• Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis (US)

  May 2023

  Myasthenia gravis (MG) is a rare neuromuscular disorder commonly caused by autoantibodies targeting acetylcholine (ACh) receptors and therefore affecting neuromuscular synaptic transmission at the…